首页> 美国卫生研究院文献>Experimental Diabetes Research >Animal Models of Diabetic Macrovascular Complications: Key Players in the Development of New Therapeutic Approaches
【2h】

Animal Models of Diabetic Macrovascular Complications: Key Players in the Development of New Therapeutic Approaches

机译:糖尿病大血管并发症的动物模型:新治疗方法发展中的关键参与者

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Diabetes mellitus is a lifelong, incapacitating metabolic disease associated with chronic macrovascular complications (coronary heart disease, stroke, and peripheral vascular disease) and microvascular disorders leading to damage of the kidneys (nephropathy) and eyes (retinopathy). Based on the current trends, the rising prevalence of diabetes worldwide will lead to increased cardiovascular morbidity and mortality. Therefore, novel means to prevent and treat these complications are needed. Under the auspices of the IMI (Innovative Medicines Initiative), the SUMMIT (SUrrogate markers for Micro- and Macrovascular hard end points for Innovative diabetes Tools) consortium is working on the development of novel animal models that better replicate vascular complications of diabetes and on the characterization of the available models. In the past years, with the high level of genomic information available and more advanced molecular tools, a very large number of models has been created. Selecting the right model for a specific study is not a trivial task and will have an impact on the study results and their interpretation. This review gathers information on the available experimental animal models of diabetic macrovascular complications and evaluates their pros and cons for research purposes as well as for drug development.
机译:糖尿病是终生的,丧失能力的代谢疾病,与慢性大血管并发症(冠心病,中风和周围血管疾病)和微血管疾病有关,导致肾脏(肾病)和眼睛(视网膜病)受损。根据目前的趋势,全世界范围内糖尿病的流行将导致心血管疾病的发病率和死亡率增加。因此,需要预防和治疗这些并发症的新颖手段。在IMI(创新药物倡议)的主持下,SUMMIT(创新型糖尿病工具的微血管和大血管硬终点的替代标记)财团正在致力于开发新型动物模型,以更好地复制糖尿病的血管并发症,并致力于可用模型的表征。在过去的几年中,随着可获得的高水平的基因组信息和更先进的分子工具,已经创建了大量模型。为特定研究选择正确的模型并不是一件容易的事,并且会对研究结果及其解释产生影响。这篇综述收集了有关糖尿病大血管并发症的可用实验动物模型的信息,并评估了它们在研究和药物开发方面的利弊。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号